SCHEMBL2464347

SCHEMBL2464347

COc1cc(C(=O)c2nc(-c3ccc(C)cc3)[nH]c2Cc2ccccc2)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 14/20 0.49
TUBB P07437 14/20 0.49
TUBA3C P0DPH7 14/20 0.49
TUBA1B P68363 14/20 0.49
TUBA4A P68366 14/20 0.49
TUBB4B P68371 14/20 0.49
TUBB3 Q13509 14/20 0.49
TUBB2A Q13885 14/20 0.49
TUBB8 Q3ZCM7 14/20 0.49
TUBA3E Q6PEY2 14/20 0.49
TUBA1A Q71U36 14/20 0.49
TUBA1C Q9BQE3 14/20 0.49
TUBB6 Q9BUF5 14/20 0.49
TUBB2B Q9BVA1 14/20 0.49
TUBB1 Q9H4B7 14/20 0.49
PDE2A O00408 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CETP P11597 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2465972 0.82 TUBB1 (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL26914660 0.75 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL725050 0.73 TUBB4A (0.53) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL724651 0.71 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL724184 0.71 TUBB4A (0.50) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL723574 0.69 LMNA (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL722476 0.67 HDAC3 (0.54) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL725347 0.67 TUBB4A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL19214633 0.67 MAPT (0.54) LMNAMAPT
SCHEMBL15135554 0.66 TUBB4A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 EP disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 EP disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 WO disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 EP disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 WO disclosed